US 10983128
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 10983128 (CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy) held by Providence Health & Services expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Providence Health & Services
- Grant date
- Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55